Lumos Pharma, Inc.
LUMODelisted Dec 12, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001126234
Lumos Pharma, Inc. was delisted on Dec 12, 2024; its insiders filed their last Form 4 on Dec 13, 2024; 29 institutions reported holding it in 13F filings for Q3 2024, worth $8.08M in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in Lumos Pharma, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
LUMO is no longer listed, and 13F filings after Q3 2024 list far fewer holders. See Q3 2024
- Institutional holders
- 0
- −29 vs. Q3 2024
- Shares held
- 0
- −2.09M (−100.0%) vs. Q3 2024
- Total value
- $0
- −$8.08M (−100.0%) vs. Q3 2024
- New holders
- 0
- 0 more added
- Sold out
- 29
- 0 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LUMO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 29 | $8.08M |
| Q2 2024 | 36 | $4.82M |
| Q1 2024 | 36 | $6.14M |
| Q4 2023 | 37 | $7.52M |
| Q3 2023 | 34 | $8.05M |
| Q2 2023 | 35 | $7.90M |
| Q1 2023 | 37 | $7.40M |
| Q4 2022 | 38 | $8.51M |
| Q3 2022 | 35 | $23.0M |
| Q2 2022 | 36 | $18.7M |
| Q1 2022 | 36 | $23.3M |
| Q4 2021 | 38 | $18.7M |
| Q3 2021 | 37 | $27.3M |
| Q2 2021 | 40 | $32.1M |
| Q1 2021 | 41 | $38.8M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Lumos Pharma, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Private Advisor Group, LLC | 0 | $0 | 0.00% | −744,513−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −362,198−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −244,082−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −213,814−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −120,651−100.0% | Sold out |
| Greenwich Wealth Management LLC | 0 | $0 | 0.00% | −76,341−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −64,981−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −55,148−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −39,825−100.0% | Sold out |
| Lion Point Capital, LP | 0 | $0 | 0.00% | −39,589−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −25,278−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −19,643−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −11,858−100.0% | Sold out |
| Wealth Advisors of Iowa, LLC | 0 | $0 | 0.00% | −11,699−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −11,237−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −11,130−100.0% | Sold out |
| Key Financial Inc | 0 | $0 | 0.00% | −10,927−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −6,557−100.0% | Sold out |
| Paladin Advisory Group, LLC | 0 | $0 | 0.00% | −4,387−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1,800−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,225−100.0% | Sold out |
| West Financial Advisors, LLC | 0 | $0 | 0.00% | −784−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −290−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −166−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Live Oak Investment Partners | 0 | $0 | 0.00% | – | Sold out |
| Jones Financial Companies LLLP | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −50−100.0% | Sold out |